Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the very first-line cure of CML-CP. Five hundred and nineteen patients with freshly diagnosed CML-CP ended up randomly assigned to get dasatinib in a dose of one hundred mg after daily (259 individuals) or https://ammonc322yqi3.newbigblog.com/profile